These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 32293353)

  • 1. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab.
    Byon IS; Kwon HJ; Kim SI; Shin MK; Park SW; Lee JE
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):534-41. PubMed ID: 25423633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sagong M; Lim S; Chang W
    Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
    Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
    Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population.
    Sen P; Bhende M; Sachidanandam R; Bansal N; Sharma T
    Indian J Ophthalmol; 2016 Dec; 64(12):908-913. PubMed ID: 28112132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T; Okano K; Kohno H; Tsuneoka H
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM; Koh HJ; Lee CS; Lee SC
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
    Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy.
    Kitajima Y; Maruyama-Inoue M; Ito A; Sato S; Inoue T; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1279-1285. PubMed ID: 32236705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
    Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
    BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
    Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
    Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.